Gregory Scott  Duncan net worth and biography

Gregory Duncan Biography and Net Worth

Greg Duncan is the Chief Executive Officer and Chairman of the Board of Directors of Virios Therapeutics. Previously, Mr. Duncan was President and Chief Executive Officer of Celtaxsys, Inc., a privately held biotech company focused on developing anti-inflammatory medicines for rare disease where he scaled the required capital to build out the organizational capability to advance both pre- clinical and clinical development candidates. Prior to Celtaxsys, he served as an Executive Committee member at Belgium based UCB, a specialty pharma entity developing and commercializing medicines for immunologic and central nervous system disorders. Before joining UCB, Mr. Duncan, while at Pfizer he held several executive U.S. and international appointments, including President of Pfizer’s $2B Latin America Operations and SVP of Marketing. His operational teams had accountability for the launches of many pharmaceutical brands including Lipitor, Zoloft, Viagra, Celebrex, Aricept, Lyrica, Cimzia, Zithromax (ZPack), Diflucan, Sutent, Rebif and Vimpat. Mr. Duncan has served as director for Biotie Therapeutics, the American Psychiatric Foundation, Bio International Organization (BIO), Southeast BIO (SEBIO and the Georgia Bio industry association groups. Greg holds a master’s degree in business administration from Emory University in Atlanta, GA, and a bachelor’s degree in economics from the State University of New York in Albany, NY.

What is Gregory Scott Duncan's net worth?

The estimated net worth of Gregory Scott Duncan is at least $149,398.60 as of August 17th, 2023. Mr. Duncan owns 57,461 shares of Virios Therapeutics stock worth more than $149,399 as of November 21st. This net worth evaluation does not reflect any other assets that Mr. Duncan may own. Additionally, Mr. Duncan receives a salary of $566,920.00 as CEO at Virios Therapeutics. Learn More about Gregory Scott Duncan's net worth.

How old is Gregory Scott Duncan?

Mr. Duncan is currently 59 years old. There are 4 older executives and no younger executives at Virios Therapeutics. Learn More on Gregory Scott Duncan's age.

What is Gregory Scott Duncan's salary?

As the CEO of Virios Therapeutics, Inc., Mr. Duncan earns $566,920.00 per year. Learn More on Gregory Scott Duncan's salary.

How do I contact Gregory Scott Duncan?

The corporate mailing address for Mr. Duncan and other Virios Therapeutics executives is , , . Virios Therapeutics can also be reached via phone at 866-620-8655 and via email at [email protected]. Learn More on Gregory Scott Duncan's contact information.

Has Gregory Scott Duncan been buying or selling shares of Virios Therapeutics?

Gregory Scott Duncan has not been actively trading shares of Virios Therapeutics over the course of the past ninety days. Most recently, on Thursday, August 17th, Gregory Scott Duncan bought 25,000 shares of Virios Therapeutics stock. The stock was acquired at an average cost of $1.25 per share, with a total value of $31,250.00. Following the completion of the transaction, the chief executive officer now directly owns 57,461 shares of the company's stock, valued at $71,826.25. Learn More on Gregory Scott Duncan's trading history.

Who are Virios Therapeutics' active insiders?

Virios Therapeutics' insider roster includes Gregory Duncan (CEO), William Pridgen (Director), and Richard Whitley (Director). Learn More on Virios Therapeutics' active insiders.

Gregory Scott Duncan Insider Trading History at Virios Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/17/2023Buy25,000$1.25$31,250.0057,461View SEC Filing Icon  
5/23/2022Buy7,500$4.52$33,900.0032,461View SEC Filing Icon  
12/21/2021Buy5,000$5.52$27,600.00View SEC Filing Icon  
4/5/2021Buy15,675$6.17$96,714.7519,579View SEC Filing Icon  
See Full Table

Gregory Scott Duncan Buying and Selling Activity at Virios Therapeutics

This chart shows Gregory Scott Duncan's buying and selling at Virios Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Virios Therapeutics Company Overview

Virios Therapeutics logo
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.
Read More

Today's Range

Now: $2.60
Low: $1.76
High: $3.03

50 Day Range

MA: $2.48
Low: $0.14
High: $4.99

2 Week Range

Now: $2.60
Low: $0.13
High: $1.04

Volume

637,000 shs

Average Volume

1,049,645 shs

Market Capitalization

$50.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.58